Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
4(31%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
23%
Ph phase_1
6
46%
Ph phase_3
3
23%
Ph phase_4
1
8%

Phase Distribution

6

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
6(46.2%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
3(23.1%)
Phase 4Post-market surveillance
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

13

all time

Status Distribution
Active(5)
Completed(5)
Other(3)

Detailed Status

Completed5
unknown3
Recruiting3
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (46.2%)
Phase 23 (23.1%)
Phase 33 (23.1%)
Phase 41 (7.7%)

Trials by Status

not_yet_recruiting18%
unknown323%
active_not_recruiting18%
recruiting323%
completed538%

Recent Activity

4 active trials
Showing 5 of 13
recruitingphase_3

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

NCT07286032
active_not_recruitingphase_3

Extension Study of Hetrombopag in Severe Aplastic Anemia

NCT04961710
recruitingphase_2

TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

NCT06478537
recruitingphase_2

Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy

NCT06433830
not_yet_recruitingphase_2

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia

NCT05944211
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07286032Phase 3

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Recruiting
NCT04961710Phase 3

Extension Study of Hetrombopag in Severe Aplastic Anemia

Active Not Recruiting
NCT06478537Phase 2

TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

Recruiting
NCT06433830Phase 2

Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy

Recruiting
NCT05944211Phase 2

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia

Not Yet Recruiting
NCT05575986Phase 4

Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy

Unknown
NCT03222843Phase 3

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Completed
NCT03557099Phase 1

A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

Completed
NCT03977805Phase 1

Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects

Completed
NCT03603132Phase 1

A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics

Completed
NCT02614846Phase 1

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Unknown
NCT02409394Phase 1

Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects

Completed
NCT02403440Phase 1

A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13